Apps Ahead For Diabetes: Q&A With DexCom’s Terry Gregg

Continuous glucose monitor developer DexCom is staking its future on an app-based platform for sensor-insulin pump systems. CEO Terrance Gregg offers an update on the company’s efforts, his thoughts on the space and the growing interest in glucose monitoring by big tech firms like Apple and Google.

As DexCom Inc. CEO Terrance Gregg sees it, smartphone apps will be central to future diabetes management, and his firm plans to be at the forefront.

The continuous glucose monitoring firm has one of the few mobile-app-centric, high-risk, class III device submissions under FDA review right...

More from Regulation

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

 

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By 

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

More from Policy & Regulation